These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 17139032)

  • 1. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline.
    Simon J; Pilling S; Burbeck R; Goldberg D
    Br J Psychiatry; 2006 Dec; 189():494-501. PubMed ID: 17139032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost-effectiveness of pharmacotherapy compared with cognitive-behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK.
    Koeser L; Donisi V; Goldberg DP; McCrone P
    Psychol Med; 2015 Oct; 45(14):3019-31. PubMed ID: 26040631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
    Wade AG; Toumi I; Hemels ME
    Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Counseling versus antidepressant therapy for the treatment of mild to moderate depression in primary care: economic analysis.
    Miller P; Chilvers C; Dewey M; Fielding K; Gretton V; Palmer B; Weller D; Churchill R; Williams I; Bedi N; Duggan C; Lee A; Harrison G
    Int J Technol Assess Health Care; 2003; 19(1):80-90. PubMed ID: 12701941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus.
    Simon GE; Katon WJ; Lin EH; Rutter C; Manning WG; Von Korff M; Ciechanowski P; Ludman EJ; Young BA
    Arch Gen Psychiatry; 2007 Jan; 64(1):65-72. PubMed ID: 17199056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan.
    Sado M; Knapp M; Yamauchi K; Fujisawa D; So M; Nakagawa A; Kikuchi T; Ono Y
    Aust N Z J Psychiatry; 2009 Jun; 43(6):539-47. PubMed ID: 19440886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic reviews of randomised clinical trials examining the effects of psychotherapeutic interventions versus "no intervention" for acute major depressive disorder and a randomised trial examining the effects of "third wave" cognitive therapy versus mentalization-based treatment for acute major depressive disorder.
    Jakobsen JC
    Dan Med J; 2014 Oct; 61(10):B4942. PubMed ID: 25283628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study.
    Scott J; Palmer S; Paykel E; Teasdale J; Hayhurst H
    Br J Psychiatry; 2003 Mar; 182():221-7. PubMed ID: 12611785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression.
    Vos T; Corry J; Haby MM; Carter R; Andrews G
    Aust N Z J Psychiatry; 2005 Aug; 39(8):683-92. PubMed ID: 16050922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.
    Jönsson B; Bebbington PE
    Br J Psychiatry; 1994 May; 164(5):665-73. PubMed ID: 7921718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of cognitive-behavioural therapy plus pharmacotherapy in inpatient treatment of depressive disorders.
    Köhler S; Hoffmann S; Unger T; Steinacher B; Dierstein N; Fydrich T
    Clin Psychol Psychother; 2013; 20(2):97-106. PubMed ID: 22095701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
    Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
    Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions.
    Chisholm D; Sanderson K; Ayuso-Mateos JL; Saxena S
    Br J Psychiatry; 2004 May; 184():393-403. PubMed ID: 15123502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial.
    Richards DA; Ekers D; McMillan D; Taylor RS; Byford S; Warren FC; Barrett B; Farrand PA; Gilbody S; Kuyken W; O'Mahen H; Watkins ER; Wright KA; Hollon SD; Reed N; Rhodes S; Fletcher E; Finning K
    Lancet; 2016 Aug; 388(10047):871-80. PubMed ID: 27461440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of an intervention to prevent depression in at-risk teens.
    Lynch FL; Hornbrook M; Clarke GN; Perrin N; Polen MR; O'Connor E; Dickerson J
    Arch Gen Psychiatry; 2005 Nov; 62(11):1241-8. PubMed ID: 16275811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis.
    Kim SY; Holloway RG
    Am J Psychiatry; 2003 Jul; 160(7):1272-6. PubMed ID: 12832241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.